The China Cardiovascular Health and Disease Report 2022 (hereinafter referred to as the "Report") summarizes the incidence, mortality and influencing factors of cardiovascular diseases in China, and points out that due to the prevalence of unhealthy lifestyles among Chinese residents, the huge population with cardiovascular disease risk factors, and the accelerated aging of the population, the incidence and mortality of cardiovascular diseases (CVD) in China are still increasing, and the inflection point of the decline of disease burden has not yet appeared.
The report estimates that the number of patients with CVD is 3300 million, including 11.39 million coronary heart disease, and about 1 million myocardial infarctions caused by coronary heart disease every year. Cardiovascular disease ranks first in the proportion of disease deaths among urban and rural residents in China, accounting for 48 of the causes of death in rural and urban areas in 202000% and 4586%;Cardiovascular disease is 2 out of every 5 deaths.
Proportion of major causes of death among urban and rural residents in China in 2020.
Coronary heart disease is the abbreviation of coronary atherosclerotic heart disease, which is the most common type of heart disease, and the clinical routine methods include drugs, interventions, and surgery. Among them, drugs** are the most commonly used interventions. With the deepening of the pathogenesis and clinical research of coronary heart disease, new evidence-based evidence and first-class drugs continue to emerge, and the first-class effect has also been significantly improved. Here is a brief introduction to the commonly used clinical drugs for coronary heart disease
1. Drugs to improve ischemia and reduce symptoms
This class of drugs mainly includes receptor blockers, nitrate drugs, calcium channel blockers, and other ** drugs, including metabolic drugs such as trimetazidine, potassium channel opener nicorandil, etc. Specific medications** are recommended as follows:
2. Drugs to prevent myocardial infarction and improve prognosis
Drugs with such effects mainly include aspirin, clopidogrel, ticagrelor, anticoagulants, receptor blockers, statins, angiotensin-converting enzyme inhibitors, or angiotensin receptor antagonists. Specifically** recommendations are as follows:
3. Related Chinese patent medicines for coronary heart disease
Coronary heart disease is defined in the field of traditional Chinese medicine as the category of "chest paralysis and heartache". Traditional Chinese medicine believes that the body, heart, and kidney yang qi are insufficient, resulting in a lack of yang in the chest;Seven emotions and internal injuries lead to qi stagnation;Unhealthy diet, overwork, damage to the spleen and stomach, phlegm turbidity;The cold evil attacks outside, causing the cold to condense the heart. The above-mentioned diseases and evil factors block the heart pulse and cause chest paralysis and heartache. Its pathogenesis is mainly based on the weakness of the heart and kidneys, mainly due to the deficiency of yang qi, and the long-term illness of yang damage and yin, yin and yang deficiency. Qi stagnation, blood stasis, cold condensation, phlegm turbidity as the standard.
In the Guidelines for the Clinical Application of Proprietary Chinese Medicine** for Coronary Heart Disease (2020 Edition), the following recommendations are made for proprietary Chinese medicines** coronary heart disease drugs:
Chinese medicine in the motherland is broad and profound, with a rich theoretical system and practical experience, and has an indispensable supplementary role in improving the symptoms of coronary heart disease. The Guidelines for the Clinical Application of Proprietary Chinese Medicines for Coronary Heart Disease (2020 Edition) further refines the indications for different proprietary Chinese medicines. For example, it is clear that compound Danshen Dripping Pill can be used in four situations: stable angina, unstable angina, qi stagnation and blood stasis syndrome type during periinterventional surgery, and acute attack of angina, and the recommended intensity is the highest level, that is, "strong recommendation". Qishen Yiqi Dripping Pill has also been "strongly recommended" in the secondary prevention of patients with stable angina pectoris after myocardial infarction. Clinical studies have confirmed that the combination of Chinese patent medicines such as Compound Danshen Dripping Pill or Qishen Yiqi Dripping Pill with Western medicine** can effectively improve patients' symptoms and improve their quality of life. It is expected that in the future, Chinese medicine will contribute more to the prevention and treatment of cardiovascular diseases and better meet the health needs of patients.
Facts**:
1] Chinese Cardiovascular Health and Disease Report Writing Group. China Cardiovascular Health and Disease Report 2022 Summary. China Circulation Magazine. 2023, 38(6): 583-612.
2] Expert Committee on Rational Use of Drugs of National Health and Family Planning Commission, Chinese Pharmacists Association. Guidelines for the rational use of drugs for coronary heart disease (2nd edition).Chinese Journal of Frontiers in Medicine (Electronic Edition).2018,10(6):1-130.
3] Standardization project team of "Guidelines for the Clinical Application of Dominant Diseases of Chinese Patent Medicine". Guidelines for the clinical application of proprietary Chinese medicines** coronary heart disease (2020).Chinese Journal of Integrative Medicine. 2021,41(4): 391-411.
4] jing-yan han.et al. pharmacology and therapeutics. 2017,177:164-177.
5] Yu Shijie. Research progress on myocardial ischemia-reperfusion injury and drug intervention[J].Journal of Intractable Diseases, 2004, 3(3): 186-188
6] Yang Qingfu, Li Cailing, Chen Jian. Effect of compound Danshen Dripping Pill on vascular endothelial function in patients with coronary heart disease[J].Journal of Xinxiang Medical College. 2003, 20(2): 127-128.
7] Li Guangping, Zheng Xintian, Wang Huaizhen, et al. Clinical effect of compound Danshen dripping pills on the intervention of acute ST-segment elevation myocardial infarction[J].Chinese Journal of Interventional Cardiology. 2011, 19(1): 24-28.
8] Dong Chenyan, Chen Haiyan, Li Yuan. Clinical efficacy of compound Danshen Dripping Pill combined with ticagrelor** angina pectoris after PCI for coronary heart disease[J].Journal of Cardiovascular and Cerebrovascular Diseases of Integrated Traditional Chinese and Western Medicine. 2022, 20(2): 292-294.
9] Cai Hongbin, Yao Zhuhua, Gao Yi. Effect of compound Danshen Dripping Pill combined with clopidogrel tablets on platelet function in patients with unstable angina[J].Journal of Traditional Chinese Medicine. 2013,54(6):500-502.